| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
|
Dahl, Kirsten
|
|
|
406 |
10499 |
p. 149-162
|
article
|
| 2 |
Building a resistance to US assaults on public health
|
Yamin, Alicia Ely
|
|
|
406 |
10499 |
p. 108-110
|
article
|
| 3 |
Cancer vaccines and the future of immunotherapy
|
Pail, Orrin
|
|
|
406 |
10499 |
p. 189-202
|
article
|
| 4 |
Cerebral palsy
|
Novak, Iona
|
|
|
406 |
10499 |
p. 174-188
|
article
|
| 5 |
Department of Error
|
|
|
|
406 |
10499 |
p. 134
|
article
|
| 6 |
Department of Error
|
|
|
|
406 |
10499 |
p. 134
|
article
|
| 7 |
Emily Mendenhall: applying anthropological thinking to medicine
|
Prasad, Aarathi
|
|
|
406 |
10499 |
p. 121
|
article
|
| 8 |
Eric Donn Bateman
|
Green, Andrew
|
|
|
406 |
10499 |
p. 126
|
article
|
| 9 |
From emergency multilateralism to resilient health diplomacy
|
Wong, Brian Li Han
|
|
|
406 |
10499 |
p. 129-130
|
article
|
| 10 |
Global immunisation monitoring in times of drastic cutbacks
|
Rau, Cornelius
|
|
|
406 |
10499 |
p. 128-129
|
article
|
| 11 |
GLP-1 and amylin receptor multiagonism with amycretin for obesity management
|
Khoo, Bernard
|
|
|
406 |
10499 |
p. 104-106
|
article
|
| 12 |
How Gavi support for RSV immunisation will advance health equity
|
Barsosio, Hellen C
|
|
|
406 |
10499 |
p. 127-128
|
article
|
| 13 |
Improving children's lives—the case for universality
|
Marmot, Michael
|
|
|
406 |
10499 |
p. 124-125
|
article
|
| 14 |
Over US$1 billion spent on European anti-gender initiatives
|
Park, Rebekka
|
|
|
406 |
10499 |
p. 119
|
article
|
| 15 |
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial
|
Tang, Jean Y
|
|
|
406 |
10499 |
p. 163-173
|
article
|
| 16 |
Reinforcing social safety for transgender and non-binary communities amidst global legislative threats
|
Restar, Arjee Javellana
|
|
|
406 |
10499 |
p. 110-113
|
article
|
| 17 |
River of life
|
Ball, Philip
|
|
|
406 |
10499 |
p. 122-123
|
article
|
| 18 |
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
|
Gasiorek, Agnes
|
|
|
406 |
10499 |
p. 135-148
|
article
|
| 19 |
Social prescribing: bringing community back to health?
|
The Lancet,
|
|
|
406 |
10499 |
p. 103
|
article
|
| 20 |
Targeting challenging RDEB skin wounds with gene therapy
|
Ebens, Christen L
|
|
|
406 |
10499 |
p. 106-108
|
article
|
| 21 |
Tracking maturity of the enabling environment for clinical trials
|
Moorthy, Vasee
|
|
|
406 |
10499 |
p. 113-116
|
article
|
| 22 |
Ukraine offers doctors payments to work in combat zones
|
Holt, Ed
|
|
|
406 |
10499 |
p. 120
|
article
|
| 23 |
Use of once-weekly insulins for type 1 diabetes
|
Russell-Jones, David
|
|
|
406 |
10499 |
p. 130
|
article
|
| 24 |
Use of once-weekly insulins for type 1 diabetes – Author's reply
|
Love, Kaitlin M
|
|
|
406 |
10499 |
p. 130-131
|
article
|
| 25 |
World Bank-financed hospitals left patients with “crushing debt”
|
Dooley, Ben
|
|
|
406 |
10499 |
p. 117-118
|
article
|
| 26 |
Worldwide trends in diabetes prevalence: the NCD-RisC study
|
Boyko, Edward J
|
|
|
406 |
10499 |
p. 131-132
|
article
|
| 27 |
Worldwide trends in diabetes prevalence: the NCD-RisC study
|
Lipscombe, Lorraine
|
|
|
406 |
10499 |
p. 132-133
|
article
|
| 28 |
Worldwide trends in diabetes prevalence: the NCD-RisC study – Authors' reply
|
Zhou, Bin
|
|
|
406 |
10499 |
p. 133-134
|
article
|
Journal description